Characteristics of 147 patients receiving cyclophosphamide and total body irradiation as myeloablative therapy followed by allogeneic transplantation
| Characteristic . | Results . |
|---|---|
| Age, y, median (range) | 35.2 ± 12.6 (2.8-58) |
| Sex, F/M | 58:89 |
| Diagnosis | |
| Chronic myeloid leukemia, chronic phase | 73 |
| Chronic myeloid leukemia, accelerated phase or blast crisis | 30 |
| Acute nonlymphocytic leukemia | 17 |
| Acute lymphocytic leukemia | 23 |
| Myelodysplastic syndrome | 3 |
| Lymphoma | 1 |
| Dose of hyperfractionated irradiation, Gy | |
| 9 | 1 |
| 12 | 61 |
| 13.2 | 68 |
| 14.4 | 17 |
| Source of donor hematopoietic stem cells | |
| HLA-matched sibling | 5 |
| HLA-mismatched family member | 3 |
| Unrelated donor | 139 |
| Prophylaxis against acute GVHD | |
| Cyclosporine or tacrolimus, methotrexate | 126 |
| Methotrexate | 1 |
| Cyclosporine or tacrolimus, methotrexate, RFT5 | 15 |
| Cyclosporine, prednisolone, BC3 | 3 |
| Prednisolone, BC3 | 2 |
| Characteristic . | Results . |
|---|---|
| Age, y, median (range) | 35.2 ± 12.6 (2.8-58) |
| Sex, F/M | 58:89 |
| Diagnosis | |
| Chronic myeloid leukemia, chronic phase | 73 |
| Chronic myeloid leukemia, accelerated phase or blast crisis | 30 |
| Acute nonlymphocytic leukemia | 17 |
| Acute lymphocytic leukemia | 23 |
| Myelodysplastic syndrome | 3 |
| Lymphoma | 1 |
| Dose of hyperfractionated irradiation, Gy | |
| 9 | 1 |
| 12 | 61 |
| 13.2 | 68 |
| 14.4 | 17 |
| Source of donor hematopoietic stem cells | |
| HLA-matched sibling | 5 |
| HLA-mismatched family member | 3 |
| Unrelated donor | 139 |
| Prophylaxis against acute GVHD | |
| Cyclosporine or tacrolimus, methotrexate | 126 |
| Methotrexate | 1 |
| Cyclosporine or tacrolimus, methotrexate, RFT5 | 15 |
| Cyclosporine, prednisolone, BC3 | 3 |
| Prednisolone, BC3 | 2 |